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Sudden cardiac death resulting from lethal ventricular arrhyth-
mias forms a major cause of mortality. The implantable
cardioverter defibrillator (ICD) has been shown to reduce
mortality in patients who survived cardiac arrest, who experi-
enced a previous myocardial infarction and have a diminished
left ventricular ejection fraction (LVEF), or who have a dilated
cardiomyopathy and an LVEF. This has been demonstrated
and verified in several randomised trials, and has subsequently
entered the guidelines (1). Consequently, the implantation rate
of ICDs has increased exponentially worldwide over the last
decade.
A case can be made that this conveys an enormous success
of medical technology to improve quality and quantity of life.
Indeed, it was recently reported that there were fewer cases of
ventricular fibrillation encountered during out-of-hospital car-
diac arrest between 2005–2008, compared with the time frame
1995–1997, which could be explained in part (33 %) by the
increased number of ICD carriers among subjects vulnerable
for sudden death.(2) However, ICDs only protect against
ventricular arrhythmia-induced cardiac arrest, and the ques-
tion arises whether some ICD candidates may not have too
many life-threatening comorbid conditions to have the chance
to experience gain in life expectancy from ICD implantation.
Therefore, Goldenberg et al. performed a post hoc analysis
of the MADIT 2 trial, and proposed a simple and easily
applicable clinical model of five risk factors associated with
the usefulness of ICD therapy.(3;4) They showed that a risk
score model including: 1) age above 70 years, 2) renal insuf-
ficiency (defined as blood urea nitrogen >26 mg/dl), 3) atrial
fibrillation, 4) NYHA class >2 and 5) a QRS complex
>120 msec on the ECG was able to predict clinical benefit
of ICD implantation. In their analysis, ICD implantation was
futile in patients with none of these risk factors, as no events
urging ICD therapy occurred. The curve of ICD benefit was U
shaped, however, and on its right side were patients with 3 or
more risk factors. These patients had no benefit from ICD
therapy, because they died from other than arrhythmic causes
such as advanced heart failure. Hence, optimal benefit from
the ICD was gained in the patient group with more than 0 but
less than 3 risk factors. It is suggested that within the popula-
tion of patients conforming to the inclusion criteria of the
randomised ICD trials, or conforming to the guidelines, pa-
tient selection may potentially be further optimised to select
those patients who will really experience net benefit from the
ICD. Despite the elegance and simplicity of their model, the
criteria proposed by Goldenberg et al. have not found their
way into the guidelines yet. One of the possible explanations
for this is that the clinical decision to abstain from ICD therapy
can be difficult, and that ICDs are readily implanted when the
patient’s life expectancy is estimated to be more than 1 year.
Estimating life expectancymay be complex at the bedside, but
a very similar set of risk factors, namely age ≥75 years,
estimated glomerular filtration rate (eGFR) ≤30 ml/min/
1.73 m2 and LVEF ≤20 % was recently reported to be associ-
ated with 2.5, 13.2 and 46.3 % mortality within the first year
after primary prevention ICD implantation for ≤1, 2 and 3 risk
factors respectively.(3) Another explanation could be that
many patients eligible for ICD therapy are beyond the age of
75 at the time the indication is set, which would, according to
the Goldenberg criteria, directly put them at least into the
intermediate risk category, and seemingly prevent the need
for further risk stratification. Given the fact that many ICD
recipients are old, the question whether advanced age is a
(relative) contraindication for ICD implantation is eminent,
but the efficacy of ICD therapy in the elderly remains largely
unknown.
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In this issue of the Netherlands Heart Journal, Anné et al.
investigated the validity of the Goldenberg risk factors
(QRS >120 msec, NYHA class >2, atrial fibrillation, de-
fined as at least one documented episode, and renal failure,
defined as eGFR <60 ml/min/1.73 m2) in patients of 75 years
or older, evidently with exclusion of age as a risk criterion.(4)
They performed a retrospective analysis of the ICD database
of two large implantation centres: the Erasmus MC and the
University Hospital in Basel, Switzerland, and selected 179
patients who were 75 years or older at the time of ICD
implantation. Furthermore, they compared survival in these
elderly ICD carriers with a sample of ICD patients of 60–
70 years from the same database, and with the general popu-
lation older than 75 years, as derived from the mortality
statistics of the Dutch national statistics agency (Centraal
Bureau voor de Statistiek, CBS).
Within the group of 179 elderly ICD carriers, patients with
2 or more risk factors had a worse prognosis than those with 0
or 1 risk factor. Median survival was 6.2, 4.2 and 3.5 years in
elderly patients with 0, 1 and ≥2 risk factors respectively.
Furthermore, the entire group of elderly patients did worse
than a random sample of ICD carriers aged 60–70 years,
derived from the same databases. This may not sound surpris-
ing, albeit that the survival curves started to deviate not earlier
than 3 years after implantation. Interestingly, elderly ICD
patients with 0 risk factors had the same mortality risk as the
age-matched general Dutch population.
Within the group of elderly ICD carriers, there was no
significant relation between the number of risk factors and
the occurrence of appropriate ICD shocks; on the other hand,
patients who did not experience appropriate therapy were
better off, as mortality in that group was significantly lower
than in the group with appropriate therapy.
Of the elderly patients who died during the observation
period, 49 % died without ever having experienced appropriate
ICD therapy. This number was 29% in the patients with no risk
factors, and amounted to 64 % in those with two or more risk
factors, underlining the notion that patients with heavy comor-
bidity die from causes other than lethal arrhythmias, and that
ICD implantation may potentially be futile in those patients.
There are, as Anné and coworkers do acknowledge and
discuss, several remarks to be made about the study. First, this
was a retrospective analysis of patients who were implanted
with an ICD, hence there is an obvious selection bias, as
patients who refused or were denied ICD implantation were
not included (which is similar to the ad hoc analysis of the
MADIT 2 trial in the Goldenberg paper (5)). Therefore, it
cannot be excluded that elderly ICD patients with 2 or more
risk factors and a poor prognosis still performed better than
similar patients without an ICD. Second, the number of pa-
tients is relatively low, and follow-up was incomplete and had
to be censored for 22 patients (12 %). This evidently puts a
confidence interval on the interpretation of the data. Third, due
to expanded indications for primary prevention implantation
after the publication of the MADIT 2 and SCD-HeFT trial in
2002 and 2005 respectively (6, 7), the mean follow-up for
patients with a primary prevention indication was shorter than
that of patients with a secondary prevention indication, as data
collection for this study already started in 1999. This may also
have introduced bias, as the patients with the longer follow-up
may be overrepresented in the mortality numbers.
Despite this, and taking into account that ICD harm, in the
form of inappropriate shocks, infection and implantation-
related complications, was not included in this analysis, the
data presented by Anné and coworkers are of considerable
importance for patients, clinicians and policymakers. They do
show, namely, that advanced age per se is not a criterion that
should affect the decision to implant an ICD. In the era of
extensive guidelines, consensus papers, decision rules, and a
limited health care budget, the decision to implant an ICD still
comes down to an individual interaction between doctor and
patient, in which the patient’s comorbidity, expectations and
conceptions need to be taken into account. Anné et al. provide
us with the necessary numbers to be able to manage these
expectations more appropriately, and to improve the care of
patients with an increased risk of (sudden arrhythmic) death.
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